Medical marijuana agency AMP German Cannabis Group introduced that it’s going to start auditing its provide chain in accordance with the European Union (EU) Good Manufacturing Process (EU-GMP) to “guarantee the standard and integrity of pharmaceutical items” as they transfer by the availability chain from the provider to the German affected person.
Legalization of medical marijuana in Germany occurred pretty lately (in 2017), whereas leisure hashish continues to stay unlawful. Nonetheless, even with medical marijuana being authorized, sufferers nonetheless face vital difficulties in procuring it as Germany contends with provide shortages and unnaturally excessive shelf costs.
This finally boils right down to the complicated actuality of legal guidelines that govern marijuana in Germany. Since marijuana continues to be labeled below narcotics and carries a state prohibition on its development, sale and distribution, home hashish fields can not exist in Germany – making sufferers rely solely on pharmaceutical imports for his or her wants.
Recognizing an enormous alternative, a number of overseas pharmaceutical firms have taken an curiosity in importing medical marijuana in Germany. A rising variety of medical doctors leap onto the hashish bandwagon yearly, endorsing hashish therapies for quite a lot of illnesses, and thus creating an ideal recipe for the medical marijuana provide chain to flourish.
For AMP, the EU-GMP certification will assist push merchandise earmarked to fulfill the best client well being and security requirements. Assembly these requirements may also guarantee a extra easy entry into the German market.
“Along with guaranteeing the suppliers’ manufacturing and working processes meet EU-GMP certification requirements, AMP’s German pharmaceutical consulting companion will audit AMP’s provide chain service suppliers throughout the fourth quarter of 2019 to make sure the standard and integrity of the pharmaceutical items is maintained throughout transportation, warehousing, dealing with, testing and distribution,” mentioned the corporate in an announcement.
The thought of EU-GMP certification aside, world hashish provide chains may also look to leverage the know-how of blockchain to convey transparency and visibility into the motion of marijuana from the sphere to the pharmacy counter. Blockchain may also guarantee accountability from each stakeholder throughout the worth chain, because the decentralized ledger know-how calls for equal participation and accountability from each social gathering concerned.
Pushing all of the stakeholders onto a single decentralized blockchain community may also eradicate prospects of counterfeit hashish merchandise making their means into the availability chain. Marijuana cultivation produces plenty of waste and a few vegetation die alongside the way in which, which makes it important to maintain an correct measure on the quantity of harvested hashish to make sure security.
AMP expects its first imports into Germany to start by the primary half of 2020. AMP can be procuring its medical hashish from two licensed producers primarily based within the state of Alberta, Canada. The provision agreements can be made extra concrete as soon as these producers clear the audit for EU-GMP certification and obtain their gross sales license from Well being Canada.
AMP will verify the medical hashish merchandise earlier than they’re transported from Canada to Frankfurt, Germany, by way of air freight. Upon touchdown in Frankfurt, the merchandise can be saved at a narcotics storage facility. The merchandise can be inspected one final time earlier than they’re cleared to be offered to German pharmaceutical wholesalers. These wholesalers will solely be allowed to promote the shares to pharmacists who’re contractually sure to AMP for his or her medical hashish provide – thus guaranteeing strict accountability over the hashish stock.